Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
Authors
- Brian Stwalley (ORCID: https://orcid.org/0009-0005-7313-045X)
- Elizabeth C. Dabrowski (ORCID: https://orcid.org/0009-0009-0923-072X)
- Wendy Verret
- Gregory A. Vidal (ORCID: https://orcid.org/0000-0003-3325-6224)
- Julie Katz (ORCID: https://orcid.org/0009-0007-5527-2678)
- Natalia Sadetsky
- Kevin Kalinsky
- Peter A. Kaufman
Institutions
- University of Vermont (US)
- Emory University (US)
- Piedmont Cancer Institute (US)
- Aetion (United States) (US)
- West Cancer Center (US)
- Gilead Sciences (United States) (US)
- Gilead Sciences (Australia) (AU)
- Vermont Cancer Support Network (US)
- Engineering Information Foundation (US)
Publication Details
- Journal
- Cancer Epidemiology Biomarkers & Prevention
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1158/1055-9965.epi-25-1459
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Myriad Genetics
- Genentech
- Daiichi Sankyo Europe